Assessing bleeding risk in patients taking anticoagulants

Journal of Thrombosis and Thrombolysis

Volumn 35, Issue 3, 2013, Pages 312-319

  Shoeb, Marwa ^a   Fang, Margaret C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticoagulation; Hemorrhage; Risk stratification; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; NONSTEROID ANTIINFLAMMATORY AGENT; THROMBIN INHIBITOR; WARFARIN;

AGING; ANEMIA; BLEEDING; BRAIN HEMORRHAGE; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONFERENCE PAPER; DEMOGRAPHY; DISEASE PREDISPOSITION; FALLING; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; MALIGNANT NEOPLASTIC DISEASE; OUTPATIENT BLEEDING RISK INDEX; PATIENT COUNSELING; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

AGE FACTORS; ANEMIA; ANTICOAGULANTS; FEMALE; HEMORRHAGE; HUMANS; KIDNEY DISEASES; MALE; PATIENT EDUCATION AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84876669222     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0899-7     Document Type: Conference Paper

References (39)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:160S-198S (Pubitemid 351892967)
2. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949-956 (Pubitemid 47393577)
3. Turpie AGG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673-1680
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151
5. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342-2352
6. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375:807-815
7. Hart RG, Pearce LA, Aguilar MI (2007) Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 147:590-592 (Pubitemid 351664513)
8. Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:257S-298S (Pubitemid 351892969)
9. Linkins L-A, Choi PT, Douketis JD (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 139:893-900
10. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG et al (2007) Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 120:700-705 (Pubitemid 47176507)
11. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N et al (2012) Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke 43:1795-1799
12. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS et al (2004) Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 141:745-752
13. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e419S-e494S
14. Beyth RJ, Quinn LM, Landefeld CS (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105:91-99 (Pubitemid 28405230)
15. Hart RG, Tonarelli SB, Pearce LA (2005) Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 36:1588-1593 (Pubitemid 40967537)
16. Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, D'Angelo A et al (2000) A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 84:805-810
17. Donzé J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J et al (2012) Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 125:773-778
18. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW (2005) Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 118:612-617 (Pubitemid 40732700)
19. Man-Son-Hing M, Nichol G, Lau A, Laupacis A (1999) Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 159:677-685 (Pubitemid 29177656)
20. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V (2006) The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 95:782-787
21. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF (2004) Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 35:2362-2367 (Pubitemid 39311264)
22. White HD, Gruber M, Feyzi J, Kaatz S, Tse H-F, Husted S et al (2007) Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 167:239-245
23. Adam SS, McDuffie JR, Ortel TL, Williams JW Jr (2012) Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med. doi: 10.7326/0003-4819-157-10-201211200-00532
24. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J et al (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123:2363-2372
25. Landefeld CS, Goldman L (1989) Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87:144-152 (Pubitemid 19201634)
26. Kuijer PM, Hutten BA, Prins MH, Büller HR (1999) Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 159:457-460 (Pubitemid 29108910)
27. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF (2006) Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 130:1390-1396 (Pubitemid 44786731)
28. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW et al (2006) Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 151:713-719 (Pubitemid 43290267)
29. Ruíz-Giménez N, Suárez C, González R, Nieto JA, Todolí JA, Samperiz AL et al (2008) Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100:26-31 (Pubitemid 351952971)
30. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093-1100
31. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N et al (2011) A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 58:395-401
32. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA et al (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349:631-639 (Pubitemid 36975995)
33. Apostolakis S, Lane DA, Guo Y, Buller H, Lip GYH (2012) Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atria. J Am Coll Cardiol 60:861-867
34. Gallego P, Roldán V, Torregrosa JM, Gálvez J, Valdés M, Vicente V et al (2012) Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol 5:312-318
35. Roldán V, Marín F, Fernández H, Manzano-Fernandez S, Gallego P, Valdés M et al (2012) Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real world" anticoagulated atrial fibrillation population. Chest. doi: 10.1378/chest.12-0608
36. Scherz N, Méan M, Limacher A, Righini M, Jaeger K, Beer H-J et al (2012) Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. J Thromb Haemost. doi: 10.1111/jth.12111
37. Donzé J, Rodondi N, Waeber G, Monney P, Cornuz J, Aujesky D (2012) Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med 125:1095-1102
38. Friberg L, Rosenqvist M, Lip GYH (2012) Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 33:1500-1510
39. Olesen JB, Lip GYH, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C et al (2011) Bleeding risk in "real world" patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost 9:1460-1467